{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-180591","form_type":"8-K","ticker":"IMA","cik":"0001835579","company_name":"ImageneBio, Inc.","filed_at":"2023-06-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.020776+00:00","generated_at":"2026-06-13T14:19:39.687628+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Ikena Oncology self-reports Nasdaq rule violation; remediated via share repurchase","bullets":["Issued 6,110,000 shares at $6.55 in May 2023 offering, inadvertently exceeding 20% threshold of pre-transaction voting shares.","Repurchased 97,500 shares from an investor to remediate the excess issuance and self-reported to Nasdaq.","Nasdaq determined compliance with Listing Rule 5635(d) is regained; matter closed with no effect on listing of IKNA common stock.","Company remains listed on The Nasdaq Global Market."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-180591","json":"https://secwatch.observer/filing/0001193125-23-180591.json","markdown":"https://secwatch.observer/filing/0001193125-23-180591.md","text":"https://secwatch.observer/filing/0001193125-23-180591.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835579/000119312523180591/0001193125-23-180591-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835579/000119312523180591/d466366d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T14:19:39.687628+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d3a7b8c3dfbbfc0d93e8792e7e2bba8fca4cbac5","claim":"ImageneBio, Inc. received a nasdaq compliance regained notice regarding shareholders (rules 5635(d)).","evidence_excerpt":"June 30, 2023, Ikena Oncology, Inc., a Delaware corporation (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) in response to a self-reported discovery and resolution of non-compliance with Listing Rule 5635(d). The letter notified the Company of the Staff’s determination that the Company had failed to comply with Listing Rule 5635(d), as well as the Staff’s determination that the Company had remediated the deficiency and regained compliance with Listing Rule 5635(d), and the matter is now closed, as further desc","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1835579/000119312523180591/0001193125-23-180591-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"compliance regained"},{"label":"Deficiency","value":"shareholders"},{"label":"Rules","value":"5635(d)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}